Loading…

In vitro activity of newer antimicrobials against penicillin non-susceptible strains of Streptococcus pneumoniae

Since the first isolation of with low penicillin susceptibility in the 1960s, resistant strains have spread over the globe, causing substantial problems in the treatment of pneumococcal infections. However, in Germany, rates of non-susceptibility are still below 5%.  Since 2009 clinical pneumococcal...

Full description

Saved in:
Bibliographic Details
Published in:Infection and drug resistance 2019-07, Vol.12, p.1889-1893
Main Authors: Hipp, Marlene, Burckhardt, Irene
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c503t-1c308c697ece634004086001b3b7525b91580f24e8aede2030d602a3bff32a4b3
cites
container_end_page 1893
container_issue
container_start_page 1889
container_title Infection and drug resistance
container_volume 12
creator Hipp, Marlene
Burckhardt, Irene
description Since the first isolation of with low penicillin susceptibility in the 1960s, resistant strains have spread over the globe, causing substantial problems in the treatment of pneumococcal infections. However, in Germany, rates of non-susceptibility are still below 5%.  Since 2009 clinical pneumococcal strains have been collected at the Center for Infectious Diseases, Heidelberg University Hospital, Germany. In this study, 56 of these strains were chosen due to their decreased penicillin susceptibility (minimal inhibitory concentration (MIC)≥0.12 µg/mL). Sixteen of these strains even showed an MIC of ≥2 µg/mL. We examined the in vitro activity of newer antimicrobials known to be active against Gram-positive bacteria. For this purpose MICs of ceftaroline, ceftobiprole, dalbavancin, delafloxacin, eravacycline, tedizolid, and telavancin were determined and evaluated. All of the 7 antimicrobial agents inhibited pneumococcal growth at concentrations of 0.5 µg/mL or lower. Currently, clinical breakpoints are only available for two substances, ceftaroline and ceftobiprole. According to these breakpoints, all MICs were below the susceptibility breakpoint; however, there was a correlation between high penicillin MICs (≥2 µg/mL) and MICs near the ceftaroline and ceftobiprole susceptibility breakpoint. The other agents showed very promising effects against all tested strains with the lowest MIC90 of 0.002 µg/mL for telavancin. Consequently, this study demonstrates the promising in vitro activity of newer antimicrobials against penicillin non-susceptible strains of .
doi_str_mv 10.2147/IDR.S202789
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_72018beaaad24f28b4346ea9e9919a12</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A602005283</galeid><doaj_id>oai_doaj_org_article_72018beaaad24f28b4346ea9e9919a12</doaj_id><sourcerecordid>A602005283</sourcerecordid><originalsourceid>FETCH-LOGICAL-c503t-1c308c697ece634004086001b3b7525b91580f24e8aede2030d602a3bff32a4b3</originalsourceid><addsrcrecordid>eNptktuL1DAUxoso7rLuk-9SEESQjrn0krwIy3obWBBcfQ5pejqToU1qkq7sf--pM64zYvKQcPLLl-TLl2XPKVkxWjZv1--_rm4ZYY2Qj7JzShtR1LLhj4_mZ9lljDuCjcu6bNjT7IxTTkRD5Hk2rV1-Z1PwuTbJ4uw-933u4CeEXLtkR2uCb60eYq432rqY8gmcNXYYrMudd0Wco4Ep2XaAPKawMIvEbQpY9cYbM8d8cjCP3lkNz7InParB5WG8yL5__PDt-nNx8-XT-vrqpjAV4amgBm9o8PpgoOYlISURNSG05W1TsaqVtBKkZyUIDR0wwklXE6Z52_ec6bLlF9l6r9t5vVNTsKMO98prq34XfNgoHZI1A6iGESpa0Fp3rOyZaEte1qAlSEmlpgy13u21prkdoTPg8J3DiejpirNbtfF3qq4pk5VEgdcHgeB_zBCTGi26NgzagZ-jYqwSTUkkbxB9-Q-683NwaNVCoQ-ScfGX2mh8gHW9x3PNIqqu0AdCKiY4Uqv_UNg7wH_1DnqL9ZMNr442bEEPaRv9MCfrXTwF3-xBTEeMAfoHMyhRSzAVBlMdgon0i2P_Htg_MeS_AEYY3Nk</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2250049238</pqid></control><display><type>article</type><title>In vitro activity of newer antimicrobials against penicillin non-susceptible strains of Streptococcus pneumoniae</title><source>Taylor &amp; Francis Open Access</source><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Hipp, Marlene ; Burckhardt, Irene</creator><creatorcontrib>Hipp, Marlene ; Burckhardt, Irene</creatorcontrib><description>Since the first isolation of with low penicillin susceptibility in the 1960s, resistant strains have spread over the globe, causing substantial problems in the treatment of pneumococcal infections. However, in Germany, rates of non-susceptibility are still below 5%.  Since 2009 clinical pneumococcal strains have been collected at the Center for Infectious Diseases, Heidelberg University Hospital, Germany. In this study, 56 of these strains were chosen due to their decreased penicillin susceptibility (minimal inhibitory concentration (MIC)≥0.12 µg/mL). Sixteen of these strains even showed an MIC of ≥2 µg/mL. We examined the in vitro activity of newer antimicrobials known to be active against Gram-positive bacteria. For this purpose MICs of ceftaroline, ceftobiprole, dalbavancin, delafloxacin, eravacycline, tedizolid, and telavancin were determined and evaluated. All of the 7 antimicrobial agents inhibited pneumococcal growth at concentrations of 0.5 µg/mL or lower. Currently, clinical breakpoints are only available for two substances, ceftaroline and ceftobiprole. According to these breakpoints, all MICs were below the susceptibility breakpoint; however, there was a correlation between high penicillin MICs (≥2 µg/mL) and MICs near the ceftaroline and ceftobiprole susceptibility breakpoint. The other agents showed very promising effects against all tested strains with the lowest MIC90 of 0.002 µg/mL for telavancin. Consequently, this study demonstrates the promising in vitro activity of newer antimicrobials against penicillin non-susceptible strains of .</description><identifier>ISSN: 1178-6973</identifier><identifier>EISSN: 1178-6973</identifier><identifier>DOI: 10.2147/IDR.S202789</identifier><identifier>PMID: 31308709</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Antibiotics ; Antimicrobial agents ; Bacteria ; Breakpoints ; Ceftaroline ; Communicable diseases ; Dalbavancin ; Delafloxacin ; Drug resistance ; Drug therapy ; Eravacycline ; Gram-positive bacteria ; Health aspects ; Infection ; Infectious diseases ; Laboratories ; Meningitis ; Methicillin ; Minimum inhibitory concentration ; Original Research ; Oxacillin ; Penicillin ; penicillin resistance ; Penicillins ; Pneumococcal infections ; Pneumonia ; Staphylococcus infections ; Strains (organisms) ; Streptococcus infections ; Streptococcus pneumoniae ; Surveillance ; susceptibility testing ; Tedizolid ; Telavancin ; Tetracyclines</subject><ispartof>Infection and drug resistance, 2019-07, Vol.12, p.1889-1893</ispartof><rights>COPYRIGHT 2019 Dove Medical Press Limited</rights><rights>2019. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 Hipp and Burckhardt. 2019 Hipp and Burckhardt.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c503t-1c308c697ece634004086001b3b7525b91580f24e8aede2030d602a3bff32a4b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2250049238/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2250049238?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768,74869</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31308709$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hipp, Marlene</creatorcontrib><creatorcontrib>Burckhardt, Irene</creatorcontrib><title>In vitro activity of newer antimicrobials against penicillin non-susceptible strains of Streptococcus pneumoniae</title><title>Infection and drug resistance</title><addtitle>Infect Drug Resist</addtitle><description>Since the first isolation of with low penicillin susceptibility in the 1960s, resistant strains have spread over the globe, causing substantial problems in the treatment of pneumococcal infections. However, in Germany, rates of non-susceptibility are still below 5%.  Since 2009 clinical pneumococcal strains have been collected at the Center for Infectious Diseases, Heidelberg University Hospital, Germany. In this study, 56 of these strains were chosen due to their decreased penicillin susceptibility (minimal inhibitory concentration (MIC)≥0.12 µg/mL). Sixteen of these strains even showed an MIC of ≥2 µg/mL. We examined the in vitro activity of newer antimicrobials known to be active against Gram-positive bacteria. For this purpose MICs of ceftaroline, ceftobiprole, dalbavancin, delafloxacin, eravacycline, tedizolid, and telavancin were determined and evaluated. All of the 7 antimicrobial agents inhibited pneumococcal growth at concentrations of 0.5 µg/mL or lower. Currently, clinical breakpoints are only available for two substances, ceftaroline and ceftobiprole. According to these breakpoints, all MICs were below the susceptibility breakpoint; however, there was a correlation between high penicillin MICs (≥2 µg/mL) and MICs near the ceftaroline and ceftobiprole susceptibility breakpoint. The other agents showed very promising effects against all tested strains with the lowest MIC90 of 0.002 µg/mL for telavancin. Consequently, this study demonstrates the promising in vitro activity of newer antimicrobials against penicillin non-susceptible strains of .</description><subject>Antibiotics</subject><subject>Antimicrobial agents</subject><subject>Bacteria</subject><subject>Breakpoints</subject><subject>Ceftaroline</subject><subject>Communicable diseases</subject><subject>Dalbavancin</subject><subject>Delafloxacin</subject><subject>Drug resistance</subject><subject>Drug therapy</subject><subject>Eravacycline</subject><subject>Gram-positive bacteria</subject><subject>Health aspects</subject><subject>Infection</subject><subject>Infectious diseases</subject><subject>Laboratories</subject><subject>Meningitis</subject><subject>Methicillin</subject><subject>Minimum inhibitory concentration</subject><subject>Original Research</subject><subject>Oxacillin</subject><subject>Penicillin</subject><subject>penicillin resistance</subject><subject>Penicillins</subject><subject>Pneumococcal infections</subject><subject>Pneumonia</subject><subject>Staphylococcus infections</subject><subject>Strains (organisms)</subject><subject>Streptococcus infections</subject><subject>Streptococcus pneumoniae</subject><subject>Surveillance</subject><subject>susceptibility testing</subject><subject>Tedizolid</subject><subject>Telavancin</subject><subject>Tetracyclines</subject><issn>1178-6973</issn><issn>1178-6973</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptktuL1DAUxoso7rLuk-9SEESQjrn0krwIy3obWBBcfQ5pejqToU1qkq7sf--pM64zYvKQcPLLl-TLl2XPKVkxWjZv1--_rm4ZYY2Qj7JzShtR1LLhj4_mZ9lljDuCjcu6bNjT7IxTTkRD5Hk2rV1-Z1PwuTbJ4uw-933u4CeEXLtkR2uCb60eYq432rqY8gmcNXYYrMudd0Wco4Ep2XaAPKawMIvEbQpY9cYbM8d8cjCP3lkNz7InParB5WG8yL5__PDt-nNx8-XT-vrqpjAV4amgBm9o8PpgoOYlISURNSG05W1TsaqVtBKkZyUIDR0wwklXE6Z52_ec6bLlF9l6r9t5vVNTsKMO98prq34XfNgoHZI1A6iGESpa0Fp3rOyZaEte1qAlSEmlpgy13u21prkdoTPg8J3DiejpirNbtfF3qq4pk5VEgdcHgeB_zBCTGi26NgzagZ-jYqwSTUkkbxB9-Q-683NwaNVCoQ-ScfGX2mh8gHW9x3PNIqqu0AdCKiY4Uqv_UNg7wH_1DnqL9ZMNr442bEEPaRv9MCfrXTwF3-xBTEeMAfoHMyhRSzAVBlMdgon0i2P_Htg_MeS_AEYY3Nk</recordid><startdate>20190701</startdate><enddate>20190701</enddate><creator>Hipp, Marlene</creator><creator>Burckhardt, Irene</creator><general>Dove Medical Press Limited</general><general>Taylor &amp; Francis Ltd</general><general>Dove</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20190701</creationdate><title>In vitro activity of newer antimicrobials against penicillin non-susceptible strains of Streptococcus pneumoniae</title><author>Hipp, Marlene ; Burckhardt, Irene</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c503t-1c308c697ece634004086001b3b7525b91580f24e8aede2030d602a3bff32a4b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antibiotics</topic><topic>Antimicrobial agents</topic><topic>Bacteria</topic><topic>Breakpoints</topic><topic>Ceftaroline</topic><topic>Communicable diseases</topic><topic>Dalbavancin</topic><topic>Delafloxacin</topic><topic>Drug resistance</topic><topic>Drug therapy</topic><topic>Eravacycline</topic><topic>Gram-positive bacteria</topic><topic>Health aspects</topic><topic>Infection</topic><topic>Infectious diseases</topic><topic>Laboratories</topic><topic>Meningitis</topic><topic>Methicillin</topic><topic>Minimum inhibitory concentration</topic><topic>Original Research</topic><topic>Oxacillin</topic><topic>Penicillin</topic><topic>penicillin resistance</topic><topic>Penicillins</topic><topic>Pneumococcal infections</topic><topic>Pneumonia</topic><topic>Staphylococcus infections</topic><topic>Strains (organisms)</topic><topic>Streptococcus infections</topic><topic>Streptococcus pneumoniae</topic><topic>Surveillance</topic><topic>susceptibility testing</topic><topic>Tedizolid</topic><topic>Telavancin</topic><topic>Tetracyclines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hipp, Marlene</creatorcontrib><creatorcontrib>Burckhardt, Irene</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Infection and drug resistance</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hipp, Marlene</au><au>Burckhardt, Irene</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro activity of newer antimicrobials against penicillin non-susceptible strains of Streptococcus pneumoniae</atitle><jtitle>Infection and drug resistance</jtitle><addtitle>Infect Drug Resist</addtitle><date>2019-07-01</date><risdate>2019</risdate><volume>12</volume><spage>1889</spage><epage>1893</epage><pages>1889-1893</pages><issn>1178-6973</issn><eissn>1178-6973</eissn><abstract>Since the first isolation of with low penicillin susceptibility in the 1960s, resistant strains have spread over the globe, causing substantial problems in the treatment of pneumococcal infections. However, in Germany, rates of non-susceptibility are still below 5%.  Since 2009 clinical pneumococcal strains have been collected at the Center for Infectious Diseases, Heidelberg University Hospital, Germany. In this study, 56 of these strains were chosen due to their decreased penicillin susceptibility (minimal inhibitory concentration (MIC)≥0.12 µg/mL). Sixteen of these strains even showed an MIC of ≥2 µg/mL. We examined the in vitro activity of newer antimicrobials known to be active against Gram-positive bacteria. For this purpose MICs of ceftaroline, ceftobiprole, dalbavancin, delafloxacin, eravacycline, tedizolid, and telavancin were determined and evaluated. All of the 7 antimicrobial agents inhibited pneumococcal growth at concentrations of 0.5 µg/mL or lower. Currently, clinical breakpoints are only available for two substances, ceftaroline and ceftobiprole. According to these breakpoints, all MICs were below the susceptibility breakpoint; however, there was a correlation between high penicillin MICs (≥2 µg/mL) and MICs near the ceftaroline and ceftobiprole susceptibility breakpoint. The other agents showed very promising effects against all tested strains with the lowest MIC90 of 0.002 µg/mL for telavancin. Consequently, this study demonstrates the promising in vitro activity of newer antimicrobials against penicillin non-susceptible strains of .</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>31308709</pmid><doi>10.2147/IDR.S202789</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1178-6973
ispartof Infection and drug resistance, 2019-07, Vol.12, p.1889-1893
issn 1178-6973
1178-6973
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_72018beaaad24f28b4346ea9e9919a12
source Taylor & Francis Open Access; Publicly Available Content Database; PubMed Central
subjects Antibiotics
Antimicrobial agents
Bacteria
Breakpoints
Ceftaroline
Communicable diseases
Dalbavancin
Delafloxacin
Drug resistance
Drug therapy
Eravacycline
Gram-positive bacteria
Health aspects
Infection
Infectious diseases
Laboratories
Meningitis
Methicillin
Minimum inhibitory concentration
Original Research
Oxacillin
Penicillin
penicillin resistance
Penicillins
Pneumococcal infections
Pneumonia
Staphylococcus infections
Strains (organisms)
Streptococcus infections
Streptococcus pneumoniae
Surveillance
susceptibility testing
Tedizolid
Telavancin
Tetracyclines
title In vitro activity of newer antimicrobials against penicillin non-susceptible strains of Streptococcus pneumoniae
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T19%3A53%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20activity%20of%20newer%20antimicrobials%20against%20penicillin%20non-susceptible%20strains%20of%20Streptococcus%20pneumoniae&rft.jtitle=Infection%20and%20drug%20resistance&rft.au=Hipp,%20Marlene&rft.date=2019-07-01&rft.volume=12&rft.spage=1889&rft.epage=1893&rft.pages=1889-1893&rft.issn=1178-6973&rft.eissn=1178-6973&rft_id=info:doi/10.2147/IDR.S202789&rft_dat=%3Cgale_doaj_%3EA602005283%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c503t-1c308c697ece634004086001b3b7525b91580f24e8aede2030d602a3bff32a4b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2250049238&rft_id=info:pmid/31308709&rft_galeid=A602005283&rfr_iscdi=true